Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0H3UR
|
|||
| Drug Name |
M3814
|
|||
| Synonyms |
MOWXJLUYGFNTAL-DEOSSOPVSA-N; M-3814; 1637542-33-6; M-3814(nedisertib); nedisertib (proposed INN); UNII-GN429E725A; GTPL9766; SCHEMBL16235559; GN429E725A; MSC2490484A; EX-A1679; example 136 [WO2014183850]; HY-101570; CS-0021723; (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol
Click to Show/Hide
|
|||
| Indication | Locally advanced rectal cancer [ICD-11: 2B92; ICD-10: C20; ICD-9: 154] | Phase 1/2 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [2] | ||
| Company |
EMD Serono Rockland, MA
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H21ClFN5O3
|
|||
| Canonical SMILES |
COC1=NN=C(C=C1)C(C2=C(C=C(C(=C2)C3=NC=NC4=C3C=CC(=C4)N5CCOCC5)F)Cl)O
|
|||
| InChI |
1S/C24H21ClFN5O3/c1-33-22-5-4-20(29-30-22)24(32)16-11-17(19(26)12-18(16)25)23-15-3-2-14(10-21(15)27-13-28-23)31-6-8-34-9-7-31/h2-5,10-13,24,32H,6-9H2,1H3/t24-/m0/s1
|
|||
| InChIKey |
MOWXJLUYGFNTAL-DEOSSOPVSA-N
|
|||
| CAS Number |
CAS 1637542-33-6
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | DNA-dependent protein kinase catalytic (PRKDC) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Non-homologous end-joining | |||
| Cell cycle | ||||
| NetPath Pathway | IL1 Signaling Pathway | |||
| Pathway Interaction Database | DNA-PK pathway in nonhomologous end joining | |||
| Coregulation of Androgen receptor activity | ||||
| Class I PI3K signaling events mediated by Akt | ||||
| BARD1 signaling events | ||||
| Reactome | Nonhomologous End-Joining (NHEJ) | |||
| WikiPathways | DNA Damage Response | |||
| Non-homologous end joining | ||||
| FAS pathway and Stress induction of HSP regulation | ||||
| Cytosolic sensors of pathogen-associated DNA | ||||
| Retinoblastoma (RB) in Cancer | ||||
| Prostate Cancer | ||||
| Double-Strand Break Repair | ||||
| Cell Cycle | ||||
| miRNA Regulation of DNA Damage Response | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03770689) Study of Peposertib in Combination With Capecitabine and Radiotherapy in Rectal Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.